Bridion(sugammadex)
Bridion (sugammadex) is an oligosaccharide pharmaceutical. Sugammadex was first approved as Bridion on 2008-07-25. It has been approved in Europe to treat neuromuscular blockade.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Trade Name
FDA
EMA
Bridion
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sugammadex sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BRIDION | Organon | N-022225 RX | 2015-12-15 | 2 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| bridion | New Drug Application | 2023-05-10 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
SUGAMMADEX SODIUM, BRIDION, ORGANON SUB MERCK | |||
| 2024-06-25 | NPP | ||
| 2024-01-22 | M-291 | ||
| 2023-06-09 | M-262 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Sugammadex Sodium, Bridion, Organon Sub Merck | |||
| RE44733 | 2026-01-27 | DS, DP | U-1794 |
HCPCS
No data
Clinical
Clinical Trials
220 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuromuscular blockade | D019148 | 1 | 6 | 13 | 28 | 9 | 56 | ||
| General anesthesia | D000768 | — | 8 | 12 | 1 | 2 | 23 | ||
| Anesthesia | D000758 | — | 1 | 6 | 6 | 2 | 14 | ||
| Delayed emergence from anesthesia | D055191 | — | 2 | — | 5 | 6 | 13 | ||
| Gallbladder diseases | D005705 | EFO_0003832 | K82.9 | — | — | — | 1 | 2 | 3 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | — | — | 3 | — | 3 |
| Pharmacokinetics | D010599 | — | — | — | 3 | — | 3 | ||
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | — | 1 | 1 | 1 | 3 | |
| Laparoscopy | D010535 | — | — | — | 3 | — | 3 | ||
| Vomiting | D014839 | HP_0002013 | R11.1 | — | — | — | 2 | — | 2 |
Show 34 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Morbid obesity | D009767 | EFO_0001074 | — | 2 | 1 | — | 1 | 3 | |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | — | 1 | — | 1 | 2 |
| Urinary retention | D016055 | HP_0000016 | R33 | 1 | 1 | 1 | — | — | 2 |
| Beta-thalassemia | D017086 | Orphanet_848 | D56.1 | — | 1 | 1 | — | — | 1 |
| Hepatoblastoma | D018197 | C22.2 | — | 1 | 1 | — | — | 1 | |
| Burns | D002056 | T30.0 | — | — | 1 | — | — | 1 | |
| Organophosphate poisoning | D062025 | — | 1 | 1 | — | — | 1 | ||
| Muscle weakness | D018908 | HP_0001324 | — | — | 1 | — | — | 1 | |
| Muscle fatigue | D018763 | — | — | 1 | — | — | 1 | ||
| Elective surgical procedures | D017558 | — | — | 1 | — | — | 1 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | 1 | — | — | — | 2 |
| Hip osteoarthritis | D015207 | EFO_1000786 | M16 | — | 1 | — | — | — | 1 |
| Inflammation | D007249 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | 2 | — | — | — | — | 2 |
| Retinal diseases | D012164 | HP_0000479 | H35.9 | 1 | — | — | — | — | 1 |
| High-frequency jet ventilation | D006611 | 1 | — | — | — | — | 1 | ||
| Anaphylaxis | D000707 | T78.2 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Delirium | D003693 | R41.0 | — | — | — | — | 2 | 2 | |
| Bariatric surgery | D050110 | — | — | — | — | 1 | 1 | ||
| Motor evoked potentials | D019054 | — | — | — | — | 1 | 1 | ||
| Cardiac catheterization | D006328 | — | — | — | — | 1 | 1 | ||
| Critical illness | D016638 | — | — | — | — | 1 | 1 | ||
| Vocal cord paralysis | D014826 | HP_0001605 | J38.0 | — | — | — | — | 1 | 1 |
| Fatal outcome | D017809 | — | — | — | — | 1 | 1 | ||
| Liver transplantation | D016031 | EFO_0010682 | — | — | — | — | 1 | 1 | |
| Pharyngitis | D010612 | R07.0 | — | — | — | — | 1 | 1 | |
| Fasciculation | D005207 | R25.3 | — | — | — | — | 1 | 1 |
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | SUGAMMADEX |
| INN | sugammadex |
| Description | Sugammadex sodium is an organic sodium salt that is the octasodium salt of sugammadex. Used for reversal of neuromuscular blockade induced by rocuronium and vecuronium in adults undergoing surgery. It has a role as a neuromuscular agent. It contains a sugammadex(8-). |
| Classification | Oligosaccharide |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)C2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O |
Identifiers
| PDB | — |
| CAS-ID | 343306-79-6 |
| RxCUI | 1726987 |
| ChEMBL ID | CHEMBL2111107 |
| ChEBI ID | — |
| PubChem CID | 6918584 |
| DrugBank | DB06206 |
| UNII ID | 361LPM2T56 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Bridion - Merck Sharp & Dohme
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,028 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,679 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more